FDA Evaluating Orlistat For Potential Serious Risks
By
Elizabeth Crawford / Email the Author / “The Tan Sheet” Feb. 9, 2009, Vol. 17, No. 006
Regulatory / Word Count: 304 / Article # 05170060005
Executive Summary
FDA is evaluating whether recent adverse event reports of rectal bleeding signal a potential serious risk identified with orlistat - the active ingredient in Roche's Rx diet drug Xenical and GlaxoSmithKline's OTC weight-loss product alli
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.